The analysis about the efficacy of Rituximab against IgM anti-myelin-associated glycoprotein antibody demtelinating neuropathy

The analysis about the efficacy of Rituximab against IgM anti-myelin-associated glycoprotein antibody demtelinating neuropathy - The analysis about the efficacy of Rituximab against IgM anti-myelin-associated glycoprotein antibody demtelinating neuropathy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027050

Enrollment

Registered

2022-07-01

Start date

2017-05-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy

Interventions

Intravenous dose of Rituximab 375mg/m2 weekly for four consecutive weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Male or female aged from 20 to 85 2. Meet the criteria of demyelinating polyneuropathy demonstrated by nerve conduction study 3. Meet the serological criteria of IgM MGUS 4. Positive anti-MAG antibody in the serum 5. Unresponsive to the past treatment: IVIg, Plasma exchange, or steroid

Exclusion criteria

Exclusion criteria: 1. Had received the treatment, including IVIg, plasma exchange, or steroid within past three months 2. Has past history of hematological malignancy such as multiple myeloma, Waldenstroms macroglobulinemia, amyloidosis, and lymphoma 3. Had received some sort of immunosuppressive therapy within past six months

Design outcomes

Primary

Measure	Time frame
INCAT(Inflammatory Neuropathy Course and Treatment) disability score	—

Secondary

Measure	Time frame
10 meter walking test serum IgM titer anti-myelin-associated glycoprotein (MAG) antibody titer	—

Countries

Japan

Contacts

Public ContactHiroo Yoshikawa

Hyogo College of Medicine Hospital Department of Neurology

hyoshika@hyo-med.ac.jp0798-45-6598

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026